Blepharospasm Clinical Trial
Official title:
Study of the Photic Blink Reflex in Patients With Blepharospasm and Increased Blinking
Verified date | April 2019 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
Some people who have increased blinking may later develop blepharospasm. Blepharospasm is a
neurological disorder that causes involuntary closing of the eyes. Researchers want to learn
more about how eyes close in response to different stimuli. They want to study this in
healthy people, people with increased blinking, and people with blepharospasm.
Objective:
To learn how light exposure affects people with blepharospasm.
Eligibility:
People ages 18 and older with blepharospasm or increased blinking, and healthy volunteers
Design:
Participants will be screened with:
Medical history
Physical exam
Neurological exam
Participants will have up to 5 visits. The number of visits will depend on the number of
tests they opt to have. They can opt to have up to 4 tests. Visits last 60-90 minutes. They
cannot drink alcohol or caffeinated drinks for at least 12 hours before visits. Visits could
include the following tests:
Evaluation of eyelid movements. This will be video recorded.
Electromyography: Small sticky electrodes are placed on the lower eyelid skin. These are
attached to wires. Muscle activity is recorded during blink reflex procedures.
Electrical stimulation: An electrode is placed close to the eyebrow. It will deliver small
electrical shocks. The strength of the shocks will be enough to provoke a blink.
Photic stimulation: A lamp is placed in front of the face. It will deliver single or paired
flashes. The flashes will be at various intervals and intensities. Participants will wear a
patch over one eye during this test.
Combination of electrical and photic stimulation
Status | Terminated |
Enrollment | 17 |
Est. completion date | April 24, 2019 |
Est. primary completion date | April 24, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: - Must be 18 years or older - For patients only: fulfill the criteria of - Primary BPS (either focal or related to segmental dystonia) in accordance with published criteria or - Excessive involuntary eyelid closure without sustained OO spasms in accordance with Conte et al + having a resting blink rate above 15 blinks per minute. - Ability to give informed consent. - Ability to comply with all study procedures. - Agree to consume no caffeine or alcohol for 12 hours before participating in the testing visits. EXCLUSION CRITERIA: Any of the following will exclude PATIENTS from the study: - Secondary causes of excessive involuntary eyelid closure such as ophthalmologist disorders involving the ocular surface, tear film, or eyelids. - Any evidence suggesting a psychogenic movement disorder such as persisting unilateral or asymmetric symptoms, paroxysmal symptoms, and other inconsistencies such as pain, associated somatizations, blinking diminished by distraction, unusual sensory tricks, or unexpected response. - Botulinum toxin treatment < 3 months prior to a testing visit. - History of chronic exposure (>3 month) to dopamine receptor blocking agents before the onset of increased blinking alone or BPS. Any of the following will exclude BOTH patients and healthy controls from the study: - Has any major medical problem other than increased blinking or dystonia in patient groups (such as decompensated chronic diseases or conditions that cause serious disability such as congestive heart failure/NYHA score greater than or equal to 2, severe COPD, advanced neoplasia, severe arthritis, HIV/AIDS, blindness). - Employees, staff or fellows of HMCS in NINDS. - Has used illegal drugs within the past 6 months based on history. The intent is to exclude those with drug use that may affect study results. - Self-reported consumption of more than 7 alcoholic drinks a week in the case of a woman and 14 alcoholic drinks a week in the case of a man. - Abnormal findings on neurologic exam (other than increased blinking or dystonia in patient groups). - Presence of anatomical or functional eyelid abnormalities other than involuntary eyelid closure or OOs spasms (including apraxia of eyelid opening, and other disorders such as tics or tardive syndromes). - Has a neurologic disorder other than increased blinking or dystonia. - Has major depression or any major mental disorders (axis I disorders). - Has had a head injury where there was a loss of consciousness for more than a few seconds. - Has a deep brain stimulator, pacemaker or other implantable electronic device subject to malfunction by electrical stimulation. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Adams WH, Digre KB, Patel BC, Anderson RL, Warner JE, Katz BJ. The evaluation of light sensitivity in benign essential blepharospasm. Am J Ophthalmol. 2006 Jul;142(1):82-87. — View Citation
Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013 Jun 15;28(7):863-73. doi: 10.1002/mds.25475. Epub 2013 May 6. Review. — View Citation
Aramideh M, Eekhof JL, Bour LJ, Koelman JH, Speelman JD, Ongerboer de Visser BW. Electromyography and recovery of the blink reflex in involuntary eyelid closure: a comparative study. J Neurol Neurosurg Psychiatry. 1995 Jun;58(6):692-8. Erratum in: J Neurol Neurosurg Psychiatry 1995 Dec;59(6):662. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Photic blink reflex recovery cycle | Single determination | ||
Secondary | Electrocutaneous blink reflex recovery cycle; Blink rate; Light Questionnaire Scale | Single determination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01686061 -
Blepharospasm Patient Survey for Patients With Blepharospasm
|
||
Completed |
NCT00535938 -
MDs on Botox Utility (MOBILITY)
|
N/A | |
Recruiting |
NCT05027997 -
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
|
Phase 2 | |
Completed |
NCT03938363 -
Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia
|
N/A | |
Completed |
NCT02947815 -
Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
|
Phase 2/Phase 3 | |
Completed |
NCT00406367 -
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
|
Phase 3 | |
Completed |
NCT00682760 -
Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm
|
Phase 3 | |
Completed |
NCT00210431 -
Post Marketing Surveillance Study of Dysport
|
||
Completed |
NCT05103202 -
Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
|
||
Completed |
NCT04423341 -
Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm
|
Phase 2/Phase 3 | |
Completed |
NCT03269123 -
A Mechanical Device for Blepharospasm
|
N/A | |
Completed |
NCT00411255 -
Brain Stimulation to Treat Blepharospasm or Meige Syndrome
|
Phase 2 | |
Completed |
NCT00500799 -
Brain Changes in Blepharospasm
|
N/A | |
Completed |
NCT00761592 -
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
|
Phase 4 | |
Completed |
NCT00001784 -
Mexiletine for the Treatment of Focal Dystonia
|
Phase 2 | |
Recruiting |
NCT04939909 -
Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm
|
Early Phase 1 | |
Completed |
NCT03508882 -
Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm
|
Phase 4 | |
Completed |
NCT01814774 -
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
|
N/A | |
Completed |
NCT00234507 -
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
|
Phase 2 | |
Recruiting |
NCT05618470 -
Wumeiwan Jiawei Fang Use in Patients With Blepharospasm
|
Phase 2/Phase 3 |